Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

DAWN - Day One Biopharmaceuticals Inc


IEX Last Trade
13.82
0.150   1.085%

Share volume: 781,900
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$13.67
0.15
1.10%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-1.77%
1 Month
-8.89%
3 Months
1.76%
6 Months
-17.77%
1 Year
3.67%
2 Year
-39.59%
Key data
Stock price
$13.82
P/E Ratio 
0.00
DAY RANGE
N/A - $14.10
EPS 
$0.00
52 WEEK RANGE
$9.67 - $18.07
52 WEEK CHANGE
-$0.01
MARKET CAP 
1.215 B
YIELD 
N/A
SHARES OUTSTANDING 
87.760 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
BETA 
1.48
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$750,070
AVERAGE 30 VOLUME 
$842,076
Company detail
CEO: Jeremy Bender
Region: US
Website: dayonebio.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

day one biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. we are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. we are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.

Recent news